BioStock: Ultimovacs keeps delivering in Q1

Q1 saw Norwegian immuno-oncology company Ultimovacs advance on a number of fronts. The company’s clinical programmes with universal cancer vaccine UV1 and adjuvant platform TET have continued to progress steadily. Moreover, milestones were reached at the preclinical level as well as the intellectual property level.

Read the article at biostock.se:

https://www.biostock.se/en/2022/05/ultimovacs-keeps-delivering-in-q1/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/